慢性乙型肝炎纵向T1ρ定量:从纤维化分期到聚乙二醇干扰素α治疗应答追踪
前瞻性研究纳入93例慢性乙型肝炎患者(轻度44例、中度26例、重度23例)及23名健康志愿者,基线行肝活检与T1ρ MRI,患者接受48周聚乙二醇干扰素α治疗,36例完成治疗后T1ρ MRI。T1ρ弛豫时间随组织学严重程度递增,与纤维化分期强相关(R²=0.77),治疗后较基线显著下降。
要点
- T1ρ弛豫时间随慢性乙型肝炎组织学严重程度递增,轻度43.94 ms、中度48.21 ms、重度53.99 ms。
- T1ρ与纤维化分期强相关(R²=0.77),与炎症分级相关(R²=0.50),均P<0.001。
- 聚乙二醇干扰素α治疗48周后T1ρ较基线显著下降(48.99 ms vs 43.57 ms,P=0.014)。
核心结论
- T1ρ MRI为评估慢性乙型肝炎患者肝病严重程度和监测治疗相关变化提供了有前景的无创工具。
研究设计与样本
- 前瞻性研究纳入93例慢性乙型肝炎患者,按组织学严重程度分为轻度44例、中度26例、重度23例,均行肝活检与基线T1ρ MRI,并接受48周聚乙二醇干扰素α治疗,其中36例完成治疗后T1ρ MRI;另设23名健康志愿者对照队列接受基线MRI扫描。
关键影像表现/征象
- 轻度慢性乙型肝炎组T1ρ弛豫时间43.94±4.88 ms,高于健康对照组的39.05±3.07 ms(P=0.028)。
- 中度组T1ρ为48.21±5.78 ms,较轻度组升高(P=0.022);重度组为53.99±5.78 ms,较中度组升高(P<0.001)。
- 所有患者组T1ρ与对照组比较差异均有统计学意义(均P<0.001)。
诊断标准与关键数值
- T1ρ弛豫时间与纤维化分期强正相关(R²=0.77,P<0.001)。
- T1ρ弛豫时间与炎症分级正相关(R²=0.50,P<0.001)。
- T1ρ与ALT(R²=0.18)、AST(R²=0.21)、胆碱酯酶(R²=0.24)呈中等相关。
临床应用与阅片要点
- T1ρ弛豫时间可无创反映慢性乙型肝炎肝纤维化分期和炎症分级,阅片时可结合定量值辅助评估病变严重程度。
- 治疗后T1ρ较基线下降(48.99±8.05 ms vs 43.57±7.20 ms,P=0.014),可用于追踪聚乙二醇干扰素α治疗相关变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: To investigate liver tissue alterations across chronic hepatitis B (CHB) progression stages and monitor therapeutic changes following pegylated interferon-α (PEG-IFNα) therapy using T1ρ magnetic resonance imaging (MRI).
MATERIALS AND METHODS: This prospective study enrolled 93 CHB patients stratified by histological severity: 44 mild, 26 moderate, and 23 severe cases. All patients underwent liver biopsy and T1ρ MRI at baseline, followed by 48 weeks of PEG-IFNα therapy. 36 patients completed post-treatment T1ρ MRI. A control cohort of 23 healthy volunteers received baseline MRI scans. Hepatic T1ρ relaxation times were compared across subgroups and correlated with histopathological parameters (inflammation grade, fibrosis stage), serum biomarkers (alanine aminotransferase [ALT], aspartate aminotransferase [AST], total bilirubin [TBIL], direct bilirubin [DBIL], cholinesterase [CHE]), and non-invasive indices (fibrosis-4 index [FIB-4]). Statistical analyses included Spearman's correlation and linear regression.
RESULTS: The mild CHB group showed elevated T1ρ relaxation time (43.94 ± 4.88 ms) versus healthy controls (39.05 ± 3.07 ms; P = 0.028), with progressive increases in moderate (48.21 ± 5.78 ms; P = 0.022 vs mild) and severe subgroups (53.99 ± 5.78 ms; P < 0.001 vs moderate). All patient groups differed significantly from controls (all P < 0.001). T1ρ relaxation times exhibited strong positive correlations with histopathological progression (R2 = 0.77 for fibrosis stage, R2 = 0.50 for inflammation grade; both P < 0.001) and moderate correlations with liver function parameters (ALT: R2 = 0.18; AST: R2 = 0.21) and synthetic markers (CHE: R2 = 0.24). Post-therapeutic T1ρ values decreased significantly compared to baseline (48.99 ± 8.05 ms vs. 43.57 ± 7.20 ms, P = 0.014).
CONCLUSION: T1ρ MRI provides a promising non-invasive tool for assessing liver disease severity and monitoring treatment-related changes in CHB patients.
引用
- Peng XG, Zhao Y, Qin Z, et al. Longitudinal T1ρ quantification in chronic hepatitis B: from fibrosis staging to pegylated interferon-α therapeutic response tracking. Eur J Radiol. 2025. PMID: 40482442. doi:10.1016/j.ejrad.2025.112203
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。